Drugs / HF1K16
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07678684 | Jun 2026 → Dec 2028 expected | glioma | HighField Biopharmaceuticals Corporation | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HF1K16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07678684 ↗ |
| Route | Intravenous | “An investigational drug administered via intravenous (IV) infusion on specified days of a 28-day cycle.” NCT07678684 ↗ |